Deuruxolitinib for treating severe alopecia areata

Deuruxolitinib (Leqselvi, Sun Pharmaceuticals) is indicated for 'the treatment of adult patients with severe alopecia areata'.

The dosage schedule is available in the summary of product characteristics for deuruxolitinib.

Deuruxolitinib costs £949.41 per pack of 60×8 mg tablets (company submission).

The company has a commercial arrangement. This makes deuruxolitinib available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is available in Sun Pharmaceuticals publication.